3-phenyl-2H-1,4-benzoxazine profile

ID Source	ID
PubMed CID	1481783
CHEMBL ID	559797
CHEBI ID	112228
SCHEMBL ID	2524831

Synonym
3-phenyl-2h-1,4-benzoxazine
smr000126152
MLS000541294
CHEBI:112228
CHEMBL559797
HMS2332I22
AKOS015993249
6T-0861
19409-26-8
YTRPWVZGQUCPKT-UHFFFAOYSA-N
SCHEMBL2524831
Q27192330
mfcd03102613

Class	Description
benzoxazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	31.6228	0.1778	14.3909	39.8107	AID2147
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	35.4813	5.6234	17.2929	31.6228	AID485281
Luciferase	Photinus pyralis (common eastern firefly)	Potency	3.0131	0.0072	15.7588	89.3584	AID588342
Nrf2	Homo sapiens (human)	Potency	15.8489	0.0920	8.2222	23.1093	AID624171
ClpP	Bacillus subtilis	Potency	31.6228	1.9953	22.6730	39.8107	AID651965
ATAD5 protein, partial	Homo sapiens (human)	Potency	6.5131	0.0041	10.8903	31.5287	AID504467
TDP1 protein	Homo sapiens (human)	Potency	14.5015	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	15.8489	0.1800	13.5574	39.8107	AID1460
thioredoxin glutathione reductase	Schistosoma mansoni	Potency	50.1187	0.1000	22.9075	100.0000	AID485364
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.1189	0.0112	12.4002	100.0000	AID1030
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	2.2387	0.2818	9.7212	35.4813	AID2326
P53	Homo sapiens (human)	Potency	79.4328	0.0731	9.6858	31.6228	AID504706
pyruvate kinase	Leishmania mexicana mexicana	Potency	8.9125	0.3981	13.7447	31.6228	AID1721; AID1722
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	28.1838	0.0355	20.9770	89.1251	AID504332
lysosomal alpha-glucosidase preproprotein	Homo sapiens (human)	Potency	35.4813	0.0366	19.6376	50.1187	AID2100
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	5.6234	0.0126	2.4518	25.0177	AID485313
ras-related protein Rab-9A	Homo sapiens (human)	Potency	3.5481	0.0002	2.6215	31.4954	AID485297
Vpr	Human immunodeficiency virus 1	Potency	25.1189	1.5849	19.6264	63.0957	AID651644
lamin isoform A-delta10	Homo sapiens (human)	Potency	35.4813	0.8913	12.0676	28.1838	AID1487
Rap guanine nucleotide exchange factor 3	Homo sapiens (human)	Potency	39.8107	6.3096	60.2008	112.2020	AID720709
Endothelin receptor type B	Rattus norvegicus (Norway rat)	Potency	8.9125	0.5623	15.1609	31.6228	AID1721
Endothelin-1 receptor	Rattus norvegicus (Norway rat)	Potency	8.9125	0.5623	15.1609	31.6228	AID1721
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
associative learning	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Rap protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
intracellular signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of GTPase activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of protein export from nucleus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of stress fiber assembly	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
establishment of endothelial barrier	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cellular response to cAMP	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein domain specific binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cortical actin cytoskeleton	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
microvillus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
endomembrane system	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
lamellipodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
filopodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular exosome	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID430475	Cytotoxicity against human HepG2 cells assessed as cell survival under hypoxic condition at 10 uM after 24 hrs by clonogenic assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
AID430473	Cytotoxicity against human HepG2 cells assessed as cell survival under normoxic condition at 10 uM after 24 hrs by clonogenic assay relative to control	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
AID430378	Cytotoxicity against human HepG2 cells in normoxic condition after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
AID430379	Cytotoxicity against human HepG2 cells in hypoxic condition after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
AID430476	Cytotoxicity against human HepG2 cells assessed as assessed as cell survival under hypoxic condition at 50 uM after 24 hrs by clonogenic assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
AID430474	Cytotoxicity against human HepG2 cells assessed as cell survival under normoxic condition at 50 uM after 24 hrs by clonogenic assay relative to control	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and biological evaluation of 2H-benzo[b][1,4] oxazine derivatives as hypoxia targeted compounds for cancer therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	3 (50.00)	24.3611
2020's	1 (16.67)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Condition	Relationship Strength	Studies
Anoxemia [description not available]	2.05	1
Benign Neoplasms [description not available]	2.05	1
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	2.05	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.05	1
Innate Inflammatory Response [description not available]	2.05	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.05	1

3-phenyl-2H-1,4-benzoxazine

Cross-References

Synonyms (13)

Drug Classes (1)

Protein Targets (22)

Potency Measurements

Biological Processes (20)

Molecular Functions (4)

Ceullar Components (8)

Bioassays (19)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

3-phenyl-2H-1,4-benzoxazine

Cross-References

Synonyms (13)

Drug Classes (1)

Protein Targets (22)

Potency Measurements

Biological Processes (20)

Molecular Functions (4)

Ceullar Components (8)

Bioassays (19)

Research

Studies (6)

Market Indicators

Research Demand Index: 12.41

Study Types

Related Conditions (6)